Production (Stage)
Tango Therapeutics, Inc.
TNGX
$1.84
-$0.025-1.34%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 30.97% | -64.53% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 30.97% | -64.53% | |||
| Cost of Revenue | 7.38% | 2.03% | |||
| Gross Profit | -4.12% | -37.70% | |||
| SG&A Expenses | 3.52% | -1.18% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.43% | 1.22% | |||
| Operating Income | -3.96% | -24.43% | |||
| Income Before Tax | -5.90% | -29.22% | |||
| Income Tax Expenses | -30.61% | -9.26% | |||
| Earnings from Continuing Operations | -5.86% | -29.15% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -5.86% | -29.15% | |||
| EBIT | -3.96% | -24.43% | |||
| EBITDA | -4.02% | -24.91% | |||
| EPS Basic | -4.30% | -28.94% | |||
| Normalized Basic EPS | -17.82% | -16.10% | |||
| EPS Diluted | -4.30% | -28.94% | |||
| Normalized Diluted EPS | -17.82% | -16.10% | |||
| Average Basic Shares Outstanding | 1.49% | 0.16% | |||
| Average Diluted Shares Outstanding | 1.49% | 0.16% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||